Matthew Chang

Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients.

Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients.

Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients.

Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients.

Nuance Pharma (Shanghai) Co., Ltd. is a Chinese innovation-focused biopharmaceutical company founded in 2014 by Yi Bo Shao and Mark Gavin Lotter. The company is based in Shanghai, China, and has subsidiaries in Germany and China. Nuance Pharma's mission is to address critical unmet medical needs in the Pacific region. The company has a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care, and iron deficiency anemia. Nuance Pharma deploys the dual wheel model that incubates a late clinical stage innovative portfolio while maintaining a self-sustainable commercial operation. The company has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain, and iron deficiency anemia. Nuance Pharma's world-class clinical and regulatory teams, visionary approach to business development, and integrated commercial platforms enable the company to continuously accelerate the access of innovative treatments to patients.